News

Public · Published

Moderna lifts revenue outlook after return to profit

Moderna raised its 2026 revenue growth outlook to 15%–25%, from previous guidance of up to 10%, citing stronger international demand for Covid-19 vaccines. Third-quarter revenue rose 29% to $1.31bn, and the company reported net income of $162m after a $200m loss a year earlier.

Published:

Updated:

What happened

Moderna raised its 2026 revenue growth outlook to 15%–25%, from previous guidance of up to 10%, citing stronger international demand for Covid-19 vaccines. Third-quarter revenue rose 29% to $1.31bn, and the company reported net income of $162m after a $200m loss a year earlier.

Confirmed

Global impact / market context

The stronger outlook suggests vaccine sales could support more revenue, while lower research spending and operating costs may help preserve cash. For investors, the return to profit and higher cash forecast could reduce concerns about funding development, though future results still depend on demand and spending.

Analyst inference

The improvement is tied to international Covid-19 vaccine demand and lower costs, rather than evidence here of broad growth across Moderna’s products. The article also reports positive late-stage results for an experimental cancer vaccine, but does not establish that it will generate sales.

Analyst inference

What to watch

  1. Watch whether international Covid-19 vaccine demand sustains the raised 2026 outlook; weaker sales could leave revenue below the company’s new growth range. Analyst inference
  2. Track research and development spending against the revised full-year estimate of approximately $2.7bn, since spending affects costs and the cash available for other work. Confirmed
  3. Follow further trial updates for intismeran, Moderna’s experimental personalised cancer vaccine developed with Merck; the reported result alone does not show whether it will reach patients or produce revenue. Analyst inference

Evidence

  • Original source link unavailable